Group News - News - 朗华制药

Home
About Langhua

About Us

Enterprise Showcase

Management Team
Solution & Service

API & Intermediates CDMO Service

Process Development Service

Manufacturing Service

Process Safety Assessment Service

Drug Product CDMO Service

Pre-clinical Drug Product R&D Service

Clinical Drug Product R&D Services

Clinical and Commercial Drug Product Manufacturing Services

Global Regulatory Submission Services

Peptide CDMO Service

Analytical Service

APl Analysis Service

Pre-formulation Analysis Service

Drug Product Analysis Service

Stability Study

Data Integrity

Support

Global CMC Filing

Project Management

Product Lifecycle Management
Technology Platform

APIs Technology Platform

Green Chemistry Technology Platform

Drug Milling/Micronization Technology

Drug Product Platform Technology

Pediatric Dosage Forms

Oral Dosage Forms

Topical Dosage Forms

Liquid Dosage Form Platform

Poorly Soluble Drug Solubilization Technology Platform

Preclinical Animal Formulation Development and Their In Vitro and In Vivo Evaluation

Salt and Polymorph Screening

Physicochemical and Biopharmaceutical Characterization of Medicinal Compounds/Drug Substances
Product Center
Compliance

GMP System

EHS System

IP Protection
News
Career
Contact Us

News Center

About Langhua Solution & Service Technology Platform Product Center Compliance News Career

Group News

Company News Recent Events Group News

Group News

Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future

Viva Biotech will continue to advance the integrated CRO-CDMO strategy, aiming to establish comprehensive and comprehensive FIC drug development services to empower our clients.